Cargando…

Impact of the introduction of a nucleic acid amplification test for Clostridium difficile diagnosis on stool rejection policies

BACKGROUND: The change from non-molecular to nucleic acid amplification tests (NAATs) is known to increase the detection of Clostridium difficile infection (CDI); however, the impact on stool rejection policies in clinical laboratories is unclear. The current guidelines have reinforced the importanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Goret, J., Blanchi, J., Floch, P., Peuchant, O., Chrisment, D., Sanchez, R., Biessy, H., Lemarié, R., Leyssene, D., Loutfi, B., Mimouni, S., Flao, T., Bébéar, C., Mégraud, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975266/
https://www.ncbi.nlm.nih.gov/pubmed/29854009
http://dx.doi.org/10.1186/s13099-018-0245-x
_version_ 1783326952475590656
author Goret, J.
Blanchi, J.
Floch, P.
Peuchant, O.
Chrisment, D.
Sanchez, R.
Biessy, H.
Lemarié, R.
Leyssene, D.
Loutfi, B.
Mimouni, S.
Flao, T.
Bébéar, C.
Mégraud, F.
author_facet Goret, J.
Blanchi, J.
Floch, P.
Peuchant, O.
Chrisment, D.
Sanchez, R.
Biessy, H.
Lemarié, R.
Leyssene, D.
Loutfi, B.
Mimouni, S.
Flao, T.
Bébéar, C.
Mégraud, F.
author_sort Goret, J.
collection PubMed
description BACKGROUND: The change from non-molecular to nucleic acid amplification tests (NAATs) is known to increase the detection of Clostridium difficile infection (CDI); however, the impact on stool rejection policies in clinical laboratories is unclear. The current guidelines have reinforced the importance of respecting strict conditions for performing tests on stool samples for CDI diagnosis. The purpose of this study was to estimate whether the implementation of molecular tests has resulted in changes in stool rejection policies between clinical laboratories that introduced NAATs and those that did not. RESULTS: A survey was conducted to evaluate the change in the number of stool samples rejected and the rejection criteria among 12 hospital laboratories in southwestern France before and after the switch from non-molecular tests to NAATs using retrospective data from June 1 till September 30, 2013 and the same period 2014. Four laboratories introduced NAATs as a second or third step in the process. A total of 1378 and 1297 stools samples were collected in 2013 and 2014, respectively. The mean number of rejected stool samples significantly increased (p < 0.001, Chi square test), with a total of 99 (7.1%) and 147 (11.3%) specimens rejected in 2013 and 2014, respectively. Notably, these laboratories had more stringent criteria and were no longer testing the stool samples of patients with CDI-positive results within 7 days. In contrast, there was a significant decrease in the rate of rejected stool samples (p < 0.001, Chi square test) in the five laboratories that did not adopt NAATs and a less stringent stool rejection policy. CONCLUSION: Nucleic acid amplification test implementation improved compliance with recommended stool rejection policies. Laboratories should follow the recommended laboratory algorithm for the CDI diagnosis combined with the correct stool rejection policy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13099-018-0245-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5975266
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59752662018-05-31 Impact of the introduction of a nucleic acid amplification test for Clostridium difficile diagnosis on stool rejection policies Goret, J. Blanchi, J. Floch, P. Peuchant, O. Chrisment, D. Sanchez, R. Biessy, H. Lemarié, R. Leyssene, D. Loutfi, B. Mimouni, S. Flao, T. Bébéar, C. Mégraud, F. Gut Pathog Research BACKGROUND: The change from non-molecular to nucleic acid amplification tests (NAATs) is known to increase the detection of Clostridium difficile infection (CDI); however, the impact on stool rejection policies in clinical laboratories is unclear. The current guidelines have reinforced the importance of respecting strict conditions for performing tests on stool samples for CDI diagnosis. The purpose of this study was to estimate whether the implementation of molecular tests has resulted in changes in stool rejection policies between clinical laboratories that introduced NAATs and those that did not. RESULTS: A survey was conducted to evaluate the change in the number of stool samples rejected and the rejection criteria among 12 hospital laboratories in southwestern France before and after the switch from non-molecular tests to NAATs using retrospective data from June 1 till September 30, 2013 and the same period 2014. Four laboratories introduced NAATs as a second or third step in the process. A total of 1378 and 1297 stools samples were collected in 2013 and 2014, respectively. The mean number of rejected stool samples significantly increased (p < 0.001, Chi square test), with a total of 99 (7.1%) and 147 (11.3%) specimens rejected in 2013 and 2014, respectively. Notably, these laboratories had more stringent criteria and were no longer testing the stool samples of patients with CDI-positive results within 7 days. In contrast, there was a significant decrease in the rate of rejected stool samples (p < 0.001, Chi square test) in the five laboratories that did not adopt NAATs and a less stringent stool rejection policy. CONCLUSION: Nucleic acid amplification test implementation improved compliance with recommended stool rejection policies. Laboratories should follow the recommended laboratory algorithm for the CDI diagnosis combined with the correct stool rejection policy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13099-018-0245-x) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-30 /pmc/articles/PMC5975266/ /pubmed/29854009 http://dx.doi.org/10.1186/s13099-018-0245-x Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Goret, J.
Blanchi, J.
Floch, P.
Peuchant, O.
Chrisment, D.
Sanchez, R.
Biessy, H.
Lemarié, R.
Leyssene, D.
Loutfi, B.
Mimouni, S.
Flao, T.
Bébéar, C.
Mégraud, F.
Impact of the introduction of a nucleic acid amplification test for Clostridium difficile diagnosis on stool rejection policies
title Impact of the introduction of a nucleic acid amplification test for Clostridium difficile diagnosis on stool rejection policies
title_full Impact of the introduction of a nucleic acid amplification test for Clostridium difficile diagnosis on stool rejection policies
title_fullStr Impact of the introduction of a nucleic acid amplification test for Clostridium difficile diagnosis on stool rejection policies
title_full_unstemmed Impact of the introduction of a nucleic acid amplification test for Clostridium difficile diagnosis on stool rejection policies
title_short Impact of the introduction of a nucleic acid amplification test for Clostridium difficile diagnosis on stool rejection policies
title_sort impact of the introduction of a nucleic acid amplification test for clostridium difficile diagnosis on stool rejection policies
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975266/
https://www.ncbi.nlm.nih.gov/pubmed/29854009
http://dx.doi.org/10.1186/s13099-018-0245-x
work_keys_str_mv AT goretj impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT blanchij impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT flochp impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT peuchanto impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT chrismentd impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT sanchezr impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT biessyh impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT lemarier impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT leyssened impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT loutfib impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT mimounis impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT flaot impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT bebearc impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies
AT megraudf impactoftheintroductionofanucleicacidamplificationtestforclostridiumdifficilediagnosisonstoolrejectionpolicies